Laura Francis, the Chief Executive Officer and a Board Member of SI-BONE, Inc., was appointed to Bruker Corporation's Board of Directors as an independent director, effective February 18, 2025. Ms. Francis is also expected to join Bruker’s Audit Committee as a financial expert after Bruker’s annual shareholder meeting in May 2025.
This appointment leverages Ms. Francis's extensive experience as a public company medtech CEO, as well as her background as a CFO and COO in both the medtech and life science tools industries. Her prior roles include serving as CFO of Bruker Corporation earlier in her career.
Bruker Corporation's chairman, president, and CEO, Frank H. Laukien, stated that Ms. Francis's experience will be valuable in guiding Bruker’s profitable growth and strategy execution. This external board appointment reflects positively on Ms. Francis's leadership capabilities and SI-BONE's standing in the industry.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.